Trial Profile
Multi-center, Open-label Pharmacokinetic Study of Subcutaneously and Intravenously Administered Treprostinil in Children With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2017
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary) ; Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Acronyms PKRemodulin; UTPKRemodulin
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 09 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.
- 09 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2017.